Gilbert, Jack A. http://orcid.org/0000-0001-7920-7001
Lynch, Susan V. http://orcid.org/0000-0001-5695-7336
Article History
Received: 1 August 2018
Accepted: 23 April 2019
First Online: 27 May 2019
Competing interests
: J.A.G. reports roles as Chief Scientific Advisor, 4inno; Scientific Advisory Board, Biome Makers, Inc.; Scientific Advisory Board, DayTwo Inc.; Scientific Advisory Board, Growcentia Inc.; Scientific Advisory Board, Holobiome Inc.; and Scientific Advisory Board, Valent BioSciences. S.V.L. reports research grants from the NIH/NIAID, NIH/NIDA, NIH/NICHD, NIH/Office of the Director and the Crohn’s and Colitis Foundation of America and the following patents and royalties: ‘Reductive prodrug cancer chemotherapy (Stan449-PRV)’; ‘Combination antibiotic and antibody therapy for the treatment of <i>Pseudomonas aeruginosa</i> infection (WO2010091189A1)’ licensed with royalties by KaloBios Inc.; ‘Therapeutic microbial consortium for induction of immune tolerance’ licensed with royalties by Siolta Therapeutics; ‘Systems and methods for detecting antibiotic resistance (WO2012027302A3)’ issued; ‘Nitroreductase enzymes (US7687474B2)’ issued; ‘Sinusitis diagnostics and treatments (WO2013155370A1)’ licensed by Reflourish, LLC; and ‘Methods and systems for phylogenetic analysis (US20120264637A1)’ issued. S.V.L. is a board member of and consultant for Siolta Therapeutics and reports personal fees for this consultancy outside the submitted work.